All In Biotech

Drug Trial Radar · NCT07044687

Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in India

A Phase 4 Study of Venetoclax in Combination With Azacitidine in Indian Subjects With Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy

Last checked: Nov 20, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Jul 24, 2025

Primary completion

Nov 2027

Study completion Nov 2027

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Jul 1, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Acute myeloid leukemia (AML) is one of the most aggressive blood cancers, with a very low survival rate and few options for participants who are unable to undergo standard induction therapy, the current standard of care. This study will assess the change in disease activity and adverse events in adult participants with acute myeloid leukemia (AML) being treated with of the combination of azacitidine and venetoclax, in India. The combination of azacitidine and venetoclax is being evaluated in the treatment of acute myeloid leukemia (AML). Participants will receive azacitidine with increasing doses of venetoclax. Around 40 adult participants with a diagnosis of AML will be enrolled in the study at approximately 15 sites in India. Participants will receive venetoclax oral tablets once daily in increasing doses until the study dose is achieved. Then ventoclax oral tablets will continue once daily thereafter. Azacitidine will be given by subcutaneous (SC) or intravenous (IV) injection on Days 1-7 of each cycle. The total study duration is approximately 29 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, and checking for side effects.

Conditions

  • Acute Myeloid Leukemia

Interventions

  • VenetoclaxDrug

    Oral Tablet

  • AzacitidineDrug

    Subcutaneous (SC) Injection

  • AzacitidineDrug

    Intravenous (IV) Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants with Treatment Emergent Adverse Events (TEAE)sTime frame: Up to Approximately 29 Months
  2. Percentage of Participants with Post-Baseline Laboratory AbnormalitiesTime frame: Up to Approximately 29 Months

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Fortis Memorial Research Institute /ID# 268697

    Gurgaon, Haryana, India · Completed

  • Healthcare Global Enterprises Limited (HCGEL) /ID# 272071

    Bengaluru, Karnataka, India · Completed

  • Mazumdar Shaw Medical Center /ID# 270677

    Bengaluru, Karnataka, India · Recruiting

  • Regional Cancer Centre /ID# 268785

    Thiruvananthapuram, Kerala, India · Recruiting

  • Tata Memorial Hospital - Mumbai /ID# 269177

    Mumbai, Maharashtra, India · Recruiting

  • LMMF's Deenanath Mangeshkar Hospital & Research Center /ID# 268781

    Pune, Maharashtra, India · Recruiting

  • Sahyadri Super Speciality Hospital /ID# 272074

    Pune, Maharashtra, India · Recruiting

  • All India Institute Of Medical Sciences - New Delhi /ID# 268357

    New Delhi, National Capital Territory of Delhi, India · Recruiting

  • Rajiv Gandhi Cancer Institute And Research Centre /ID# 268293

    New Delhi, National Capital Territory of Delhi, India · Completed

  • All India Institute Of Medical Sciences - Bhubaneswar /ID# 274879

    Bhubaneswar, Odisha, India · Recruiting

  • Apollo Cancer Centre /ID# 268780

    Chennai, Tamil Nadu, India · Recruiting

  • Cancer Institute (Wia) /ID# 268695

    Chennai, Tamil Nadu, India · Recruiting

  • Christian Medical College Vellore /ID# 279587

    Vellore, Tamil Nadu, India · Recruiting

  • Basavatarakam Indo American Cancer Hospital & Research Institute /ID# 268692

    Hyderabad, Telangana, India · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.